study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
LONG-LON13-01,2017,randomized controlled trial,SMD,0.3274,0.1395,0.5153,97,89,low,10.1234/long-lon13-01,longevity-journal-01,cellular_ageing,Adults with cellular ageing concerns,None reported,13
LONG-LON13-02,2022,randomized controlled trial,SMD,0.322,0.1517,0.4923,80,73,low,10.1234/long-lon13-02,longevity-journal-02,cellular_ageing,Adults with cellular ageing concerns,Transient headache,11
LONG-LON13-03,2013,randomized controlled trial,SMD,0.3166,0.1639,0.4693,93,88,some concerns,10.1234/long-lon13-03,longevity-journal-03,cellular_ageing,Adults with cellular ageing concerns,Mild GI discomfort,10
